Actively Recruiting
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
Led by Oui Therapeutics, Inc. · Updated on 2026-01-05
40
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
Sponsors
O
Oui Therapeutics, Inc.
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
CONDITIONS
Official Title
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with posttraumatic stress disorder (PTSD)
- Anxiety Sensitivity Index 3 (ASI-3) score above 24
- PTSD Checklist for DSM-V (PCL-5) score above 30
- Understands and speaks English
- Has access to a smartphone connected to the internet
You will not qualify if you...
- Anxiety Sensitivity Index 3 (ASI-3) score of 24 or lower
- PTSD Checklist for DSM-V (PCL-5) score of 30 or below
- No diagnosis of PTSD
- Active psychosis
- Acute intoxication during study baseline
- Enrolled in another treatment research study
- Medical illness preventing completion of interoceptive exposure exercises
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Florida State University
Tallahassee, Florida, United States, 32306
Actively Recruiting
Research Team
B
Brian Keenaghan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here